Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Other Operating Expenses (2016 - 2025)

United Therapeutics' Other Operating Expenses history spans 17 years, with the latest figure at $103.4 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 36.23% year-over-year to $103.4 million; the TTM value through Dec 2025 reached $384.4 million, up 24.12%, while the annual FY2025 figure was $384.4 million, 24.12% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $103.4 million at United Therapeutics, up from $100.9 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $150.0 million in Q2 2021 and bottomed at $25.9 million in Q1 2022.
  • The 5-year median for Other Operating Expenses is $72.0 million (2023), against an average of $72.8 million.
  • The largest annual shift saw Other Operating Expenses crashed 82.12% in 2021 before it surged 115.82% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $34.6 million in 2021, then skyrocketed by 69.94% to $58.8 million in 2022, then grew by 20.75% to $71.0 million in 2023, then rose by 6.9% to $75.9 million in 2024, then soared by 36.23% to $103.4 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Other Operating Expenses are $103.4 million (Q4 2025), $100.9 million (Q3 2025), and $87.6 million (Q2 2025).